Novel Application of Mixed Solvency Concept to Develop and Formulate Dry Powder Injection for Reconstitution of a Poorly Water Soluble Drug, Amlodipine Besylate and their Evaluations

Yashi Thakur, R.K. Maheshwari*

Shri G.S. Institute of Technology and Science, 23, Park Road, Indore 452003 (M.P.), India

INTRODUCTION

One of the difficult tasks that become a problem in the formulation development of a drug with low aqueous solubility is solubility enhancement. The low water solubility of drugs frequently presents substantial challenges in developing formulations with sufficiently high bioavailability, prohibiting effective drug usage. Dr. R.K. Maheshwari "mixed solvency concept" in 2009. Mixed solvency concept could be applied as a tool to overcome the solubility challenges in present research. It has several advantages over the other methods of solubilisation. Advantages of mixed solvency are many which include - It being a safe and ecofriendly method, reduces the risk for use of toxic and harmful organic solvents. Also, it offers the expected enhancement in drug solubility and therefore enhanced achievable drug load. The reduction in individual concentration of each solid solubiliser resulting in reduction in individual toxic effects. It does not need chemical modification of hydrophobic drugs as in cases of complexation or derivatization or related toxicity. It is applicable in many pharmaceutical areas such as development of formulation, analysis of drug by UV spectra or TLC analysis or extraction of drug in Pharmacognosy field etc. A vast number of poorly soluble drugs have had their formulations developed using the mixed solvency approach. Followings are the formulations made by using mixed solvency concept.1-41

Formulations made by using mixed solvency concept

- Oily injection, Aqueous injection, Dry powder injection
- Solid dispersion, Liquisolid system, Liquid oral, Gel based forms
- Syrup(in solution form), Topical solutions
- Fast dissolving oral films, Vaginal films, Microsphere, Niosomes, SEDDS
MATERIALS AND METHODS
Amlodipine besylate drug was obtained as a gift sample from MCW Healthcare Private Limited, Indore. Milli-Q water was used in this study. Other chemicals used were of analytical grade.

- UV SPECTROPHOTOMETRIC ANALYSIS OF DRUG, AMLODIPINE BESYLATE
In a volumetric flask with a capacity of 500 ml, 50 mg of amlodipine besylate (accurately weighed) and 400 ml of milli-Q water (Type 1 ultrapure water) were taken. The flask was then shaken thoroughly to dissolve the drug. The volume was then made up to 500 ml with Milli-Q water to form a stock solution with a concentration of 100 μg/ml. To obtain a dilution of 20 μg/ml concentration, a 10 ml stock solution was diluted up to 50 ml. The resultant solution was scanned on a Shimadzu-1700 UV spectrophotometer between 200 and 400 nm against Milli-Q water. Figure 1 illustrates the spectrum.

- MELTING POINT DETERMINATION
The open capillary technique was used to determine the drug's melting point. The melting range of the drug sample was measured using the Analog melting point test apparatus after it was packed in the capillary. The melting point range of the drug sample was 202-207 °C, similar to the literature value.

- PREPARATION OF CALIBRATION CURVE OF DRUG, AMLODIPINE BESYLATE IN WATER (MILLI-Q)
 Fifty milligram of amlodipine besylate drug was weighed and transferred to a 10 ml volumetric flask. To dissolve the drug (amlodipine besylate), 30 percent sodium caprylate solution (approximately 8 ml) was added and volume made up to 10 ml to achieve the resulting 5000 μg/ml solution (stock solution). Appropriate dilutions were made from stock solution with Milli-Q water in concentration range of 20-100 μg/ml. Using a double beam UV visible spectrophotometer (Shimadzu 1700) at 368 nm against the reagent blanks respectively, the absorbance of the resulting drug solutions were observed. The data is recorded in table 1 and described graphically in fig 2.

Table 1: Absorbance data for calibration curve of amlodipine besylate in water (Milli-Q)

| S.No. | Concentration (μg/ml) | Absorbance (mean ± S.D.) (n=3) |
|-------|-----------------------|-------------------------------|
| 1     | 0                     | 0                             |
| 2     | 20                    | 0.215 ± 0.0097                |
| 3     | 40                    | 0.427 ± 0.0130                |
| 4     | 60                    | 0.631 ± 0.0132                |
| 5     | 80                    | 0.850 ± 0.0170                |
| 6     | 100                   | 1.064 ± 0.0576                |

- APPROXIMATE SOLUBILITY DETERMINATION IN VARIOUS AQUEOUS SOLUTIONS OF SOLID SOLUBILISERS (MIXED BlENDS)
For approximate solubility determination of drug (amlodipine besylate) in Milli-Q water, 1 ml of blend was taken in 10 ml volumetric flask then 5 mg of drug amlodipine was added to it and this flask was shaken for about 15-20 minutes by vortex shaking (Remi cm 101 plus). If the drug was entirely dissolved and give a clear solution, again 5 mg of drug was added to the flask (volumetric) and the flask was shaken for about 15-20 minutes to get it dissolved. The same method was repeated until a turbid solution was obtained even after 15-20 minutes shaking. For each blend the same method was performed. The results of approximate solubility of amlodipine besylate are shown in Table 2.
Table 2: Results of approximate solubility studies of amlodipine besylate in various aqueous solutions of solubilisers.

| S. No. | Blends | The composition of blends (w/v) | Approximate solubility (mg/ml) |
|--------|--------|---------------------------------|-------------------------------|
| 1.     | B-A    | Sodium benzoate- 5% Sodium caprylate- 10% Lysine HCl- 5% PVP K-25- 5% | 40 |
| 2.     | B-B    | Sodium benzoate- 5% Sodium caprylate- 5% Niacinamide- 2.5% β-cyclodextrin- 2.5% Sodium acetate- 5% | 15 |
| 3.     | B-C    | Sodium benzoate- 5% Sodium acetate- 5% Sodium caprylate- 5% Poloxamer 407- 5% PVP K-25- 5% | 30 |
| 4.     | B-D    | Sodium caprylate- 5% Sodium acetate- 5% Sodium benzoate- 5% PVP K-25- 5% | 30 |
| 5.     | B-E    | Sodium caprylate- 5% Sodium citrate- 5% Niacinamide- 2.5% Lysine HCl- 2.5% Sodium benzoate- 5% PVP K-25- 5% | 30 |
| 6.     | B-F    | L-Arginine- 5% Poloxamer 407- 5% Sodium citrate- 5% | 15 |
| 7.     | B-G    | L-Arginine- 5% Poloxamer 407- 5% Sodium benzoate- 5% PVP K-25- 5% | 35 |
| 8.     | B-H    | L-Arginine- 5% Sodium citrate- 5% Sodium benzoate- 5% Poloxamer 407- 5% Sodium acetate- 5% | 25 |
| 9.     | B-I    | Sodium benzoate- 5% Poloxamer 407- 5% L-Arginine- 5% PVP K-25- 5% Benzoic acid- 5% | 30 |
DETERMINATION OF EQUILIBRIUM SOLUBILITY OF DRUG, AMLODIPINE BESYLATE IN MILLI-Q WATER.

In order to find out the equilibrium solubility of drug (amlodipine besylate) in Milli-Q water, excess amount of drug was weighed and added to the vial of capacity 20 ml with Milli-Q water and was capped and sealed with aluminum caps. The vial was shaken for 24 hours on the mechanical bath shaker (SciTech) and was kept untouched for 24 hours. Whatman filter paper (Grade no. 41) was used to filter the drug solution. Aliquot of filtrate was sufficiently diluted with Milli-Q water. The UV-Visible spectrophotometer (Shimadzu 1700) was used to analyze the solution. Then, equilibrium solubility of the drug, amlodipine besylate was calculated by using the calibration curve. The result is presented in Table 3.

| S.No. | Solvent | Solubility |
|-------|---------|------------|
| 1.    | Milli-Q water | 0.111 (w/v) |

SELECTION OF BLENDS OF SOLUBILISERS FOR DRY POWDER INJECTION FOR RECONSTITUTION

Based on the results of the solubility tests, three blends with solubility of drug (amlodipine besylate) of greater than 15 mg/ml were chosen. Further blend selection was based on the solubility enhancement ratio. Blends B-A, B-D, and B-M were selected on the basis of desired solubility with fewer solubilisers. It was decided to make 10 mg/ml of amlodipine besylate injection using solubilisers. Tables 4, 5 and 6 illustrate the formulations proposed.

Table 4: Formulation DIF1 (Drug injection formulation-1)

| S. No. | Ingredients  | Formula for 10 mg /1ml | Formula for 50 ml batch |
|--------|--------------|------------------------|-------------------------|
| 1      | Sodium benzoate | 50                     | 2.5 gm                  |
| 2      | Sodium caprylate | 100                    | 5 gm                    |
| 3      | Lysine HCL  | 50                     | 2.5 gm                  |
| 4      | PVP K-25  | 50                     | 2.5 gm                  |
| 5      | Amlodipine besylate | 10                    | 0.5 gm                  |
Table 5: Formulation DIF2 (Dry injection formulation-2)

| S. No. | Ingredients         | Formula for 10 mg /1ml | Formula for 50 ml batch |
|--------|---------------------|------------------------|-------------------------|
| 1      | Sodium caprylate    | 50                     | 2.5 gm                  |
| 2      | Sodium acetate      | 50                     | 2.5 gm                  |
| 3      | Sodium benzoate     | 50                     | 2.5 gm                  |
| 4      | PVP K-25            | 50                     | 2.5 gm                  |
| 5      | Amlodipine besylate | 10                     | 0.5 gm                  |

Table 6: Formulation DIF3 (Dry injection formulation-3)

| S. No. | Ingredients         | Formula for 10 mg /1ml | Formula for 50 ml batch |
|--------|---------------------|------------------------|-------------------------|
| 1      | Poloxamer 407       | 100                    | 5 gm                    |
| 2      | Lysine HCl          | 50                     | 2.5 gm                  |
| 3      | Sodium caprylate    | 100                    | 5 gm                    |
| 4      | Amlodipine besylate | 10                     | 0.5 gm                  |

- FORMULATION OF DRY POWDER INJECTION FOR RECONSTITUTION

The dry powder injections for reconstitution were prepared in accordance with the formulation details provided in the preceding tables 4, 5 and 6. The process is provided below.

All solubilisers were passed through sieve number 80 in order to individually reduce the particle size. All solubilisers and drug were weighed and blended with the aid of pestle and mortar using geometric dilution method. The combined mixture was then mixed manually using plastic bag and then the powder was passed through sieve no 80. The ready mixture was then put in 10 ml vials, then they were capped and sealed.

[Formulations DIF1- 260 mg per vial, DIF2- 210 mg per vial, and DIF3- 260 mg per vial were filled]. Each vial was containing 10 mg of amlodipine besylate.

- EVALUATION OF DRY POWDER INJECTION FOR RECONSTITUTION

The prepared formulations were subjected for various evaluation parameters.

A. DETERMINATION OF DRUG CONTENT OF DRY POWDER INJECTION FORMULATION

To assess the drug content, the 260 mg powder of DIF1 formulation (equivalent to 10 mg drug) was transferred to a 500 ml volumetric flask and about 400 ml Milli-Q water was added and then flask was shaken to solubilise it. After complete dissolution, the volume was made up to 500 ml with Milli-Q water and absorbance of this solution was noted at 368 nm. By using the calibration curve, drug content was determined. The same procedure was repeated with DIF2 (210 mg formulation powder equivalent to 10 mg drug) and DIF3 (260 mg formulation powder equivalent to 10 mg drug) and table 7 shows the outcomes.

Table 7: Drug content of reconstituted injection formulations

| Formulation name | Amount of drug (mg) |
|------------------|---------------------|
| DIF1             | 9.787               |
| DIF2             | 9.925               |
| DIF3             | 9.925               |

B. pH STUDY OF RECONSTITUTED INJECTION

The pH of the reconstituted injection was determined using a digital pH meter (Cyber Scan 510, Utech Instruments, Singapore). Table 8 illustrates the observed results.

Table 8: pH values of reconstituted injection formulations

| Formulation name | pH  |
|------------------|-----|
| DIF1             | 6.51|
| DIF2             | 6.72|
| DIF3             | 6.54|

C. DETERMINATION OF RECONSTITUTION TIME

To determine the reconstitution time, Milli-Q water (1 ml) was used to dissolve the dry injectable formulation for all batches, and the time was recorded to obtain the clear solution. Table 9 shows the results of reconstitution time.

Table 9: Reconstitution times of various formulations

| Formulation name | Reconstitution time |
|------------------|---------------------|
| DIF1             | 58 sec              |
| DIF2             | 36 sec              |
| DIF3             | 4 min 10 sec        |

D. CLARITY TESTING OF RECONSTITUTED INJECTION

By visually examining the externally clean vial, the clarity examination of the reconstituted product was carried out and viewed against black and white background. Results of the clarity testing of the reconstituted developed injection formulation are shown in table 10.

Table 10: Results of clarity testing of various reconstituted injections

| Formulation name | Clarity |
|------------------|---------|
| DIF1             | Clear   |
| DIF2             | Clear   |
| DIF3             | Clear   |

E. THIN LAYER CHROMATOGRAPHIC STUDIES

In order to know the interaction between drug and solubilisers, thin layer chromatography studies were performed. An aluminum support silica gel 60 matrix TLC plate was used. One percent methanolic solution of amlodipine besylate pure drug was prepared and the aqueous solution (1%) of amlodipine besylate in B-A, B-D and B-M were prepared and all were spotted with the aid of capillary tube. Then, the plates were left in air for sufficient
time to dry and then were transferred to a saturated jar with the solvent system containing 12.5 % w/v sodium caprylate and 7.5 % w/v sodium acetate solution (aqueous) as mobile phase.

The mobile phase was allowed to run for about 4.5 cm. Finally, the plates were allowed to air dry and were observed for visualization of spots by UV chamber. The respective Rf values were determined and recorded in table 11.

**Table 11: Rf values of amlodipine besylate in TLC study**

| Solvent system | Adsorbent | Drug | DIF1 | DIF2 | DIF3 |
|---------------|-----------|------|------|------|------|
| Sodium caprylate (12.5%) + Sodium acetate (7.5%) | Silica Gel | 0.76  | 0.70  | 0.73  | 0.66  |

**Inference:** As per the observation of TLC study, there is no significant change in Rf values of amlodipine besylate pure drug and the drug solubilised in blend solutions. From the results of TLC study, it can be concluded that there is no reaction of drug (amlodipine besylate) with solubilisers.

**F. DILUTION STUDY OF RECONSTITUTED INJECTION**

Series of dilutions were done by diluting reconstituted injection of amlodipine besylate (formulation DIF1, DIF2, and DIF3) with different diluents, normal saline (0.9% Sodium chloride) and 5% dextrose solution. The diluted products were observed for any precipitation up to 24 hours. The observations were recorded in Table 12, 13 and 14.

**Table 12: Dilution profile of reconstituted solution of formulation DIF1**

| Dilution | Time (hrs.) | Normal saline solution | 5% dextrose solution |
|----------|-------------|------------------------|----------------------|
|          |             | 1 | 2 | 4 | 6 | 8 | 24 | 1 | 2 | 4 | 6 | 8 | 24 |
| 1:1      | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 1:5      | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 1:10     | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 1:20     | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 1:30     | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 1:40     | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 1:50     | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 1:100    | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 1:500    | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |

↑= NO Precipitation, ↓= Precipitation

**Table 13: Dilution profile of reconstituted solution of formulation DIF2**

| Dilution | Time (hrs.) | Normal saline solution | 5% dextrose solution |
|----------|-------------|------------------------|----------------------|
|          |             | 1 | 2 | 4 | 6 | 8 | 24 | 1 | 2 | 4 | 6 | 8 | 24 |
| 1:1      | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 1:5      | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 1:10     | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 1:20     | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 1:30     | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 1:40     | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 1:50     | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 1:100    | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |
| 1:500    | ↑           | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ |

↑= NO Precipitation, ↓= Precipitation
**RESULTS AND DISCUSSION**

The primary goal of this research work was to facilitate the innovative use of the mixed solvency principle in the formulation of dry powder injection of drugs which are poorly soluble in water, as well as to reduce the harmful effects of solubilizers by minimizing individual solubilizers concentrations those solubilisers used for solubility enhancement.

The drug, amlodipine besylate was chosen for this research work because it is poorly water soluble. To prepare the parenteral preparation (dry powder injection for reconstitution of amlodipine besylate), solubility tests were performed utilizing a variety of physiologically suitable solubilizers.

A sample of the bulk drug (amlodipine besylate) was obtained and characterized using UV, DSC, and melting point studies. The outcomes of the experiments were consistent with those described in official compendia, hence the sample obtained was employed for further research.

In the current study, the amlodipine besylate drug sample was subjected to various characterization parameters. The melting range of the drug was calculated using the open capillary method and found to be 202-207 °C. UV spectrophotometric analysis showed the peak at 368 nm. The characterization result of the drug sample obtained confirmed that it was amlodipine besylate, hence it was used for further research.

The calibration curve of the drug, amlodipine besylate in Milli-Q water was developed during the preformulation studies. The absorbances at 368 nm of solution or pure drug and drug with solubilisers are nearly same therefore no interference was shown by the excipients in the UV visible estimation of drug amlodipine besylate at 368 nm.

Various aqueous solutions of mixed blend solubilisers (sodium benzoate, sodium caprylate, sodium acetate, sodium citrate, β-cyclo dextrin, lysine HCl, poloxamer 407, L-arginine and niacinamide) were used to study the solubility of amlodipine besylate. The approximate solubility of drug in blend-A was 4 percent, in blend-D was 3 percent and in blend-M was 2.5 percent.

Over the course of a month, drug-excipient interactions were studied, and no incompatibility between the drug and the chosen excipients was observed.

Based on the desired solubility, the above three mixed blends were chosen for batch formation for dry powder injection for reconstitution. For development and formulation of dry powder injection for reconstitution of amlodipine besylate, mixed blends containing only solid solubilizers were selected which are based on the solubility studies, these are B-A, B-D and B-M. Formulations were made by geometric dilution method with the help of mortar and pestle and then mixing in a plastic bag manually, passed through a sieve no 80 to reduce the particle size. All the developed formulations (DIF1, DIF2 and DIF3) were then subjected to various evaluations; pH of reconstituted injections was found to be physiologically compatible, reconstitution time was found to be 58 sec, 36 sec and 1 min 10 sec respectively. all the developed injection formulations were clear after reconstitution. Preparations did not show any precipitation during dilution studies in different dilution ratios.

**REFERENCES:**

1. Michael J, Akers, Parenteral Preparation: Chapter 26: 495.
2. United States Pharmacopoeia, 30 National Formulary 25. The United States Pharmacopoeial Convention Incorporation: Rockville, 2007; MD, 33.
3. Indian Pharmacopoeia, The Indian Pharmacopoeia Commission; 2007 Ghaziabad, 36.
4. Maheshwari RK, Shilpkar R, Formulation development and evaluation of injection of poorly soluble drug using mixed solvency concept, International Journal of Pharma and Biosciences, 2012; 3(1):179-189.
5. Solanki SS, Soni LK, Maheshwari RK, Study on mixed solvency concept in formulation development of aqueous injection of poorly water soluble drug, Journal of Pharmaceutics, 2013; 1-8.
6. Pawar PB, Rawat S, Mahajan YY, Galgate UC, Maheshwari RK, Formulation development and evaluation of aqueous injection of poorly soluble drug made by novel application of mixed solvency concept, International Journal of Drug Delivery, 2013; 5(2):152-166.
7. Solanki SS, Soni LK, Maheshwari RK, Solubilization of poorly water soluble drug using mixed solvency approach for aqueous injection, Journal of Pharmaceutical Research International, 2014; 4(5):549-568.

---

**Table 14: Dilution profile of reconstituted solution of formulation DIF3**

| Dilution | Normal saline solution | Time (hrs.) | 5% dextrose solution |
|----------|------------------------|-------------|---------------------|
| 1:1      | ↑                      | ↑           | ↑                   |
| 1:5      | ↑                      | ↑           | ↑                   |
| 1:10     | ↑                      | ↑           | ↑                   |
| 1:20     | ↑                      | ↑           | ↑                   |
| 1:30     | ↑                      | ↑           | ↑                   |
| 1:40     | ↑                      | ↑           | ↑                   |
| 1:50     | ↑                      | ↑           | ↑                   |
| 1:100    | ↑                      | ↑           | ↑                   |
| 1:500    | ↑                      | ↑           | ↑                   |

↑ = NO Precipitation, ↓ = Precipitation
8. Gour V, Garg A, Shukla A, Yadav AK, Development and evaluation of metronidazole injection by mixed solvency approach, Asian Journal of Bionanomaterial, 2014; 2(1):38-45.

9. Gayakwad PS, Gavit AV, Rajput PV, Bari MM, Barhate SD, Maheshwari RK, Formulation development and evaluation of an aqueous injection of gal+taxolaxin by novel mixed solvency technique, World Journal of Pharmaceutical Research, 2014; 3 (4):1642-1664.

10. Solanki SS, Development of parenteral formulation of poorly water soluble drugs: the role of novel mixed-solvency concept, Asian Journal of Pharmaceutics (AJP), 2017; 11(1):1-10.

11. Maheshwari N, Maheshwari RK, Formulation development of dry injection for reconstitution of a poorly water soluble drug, candesartan cilexetil, using mixed solvency concept and their evaluations, International Journal of Science and Research (IJSR), 2018; 8(12):1313-1320.

12. Padiyar A, Maheshwari RK, Novel dry injection for reconstitution of aspirin using solid solubilisers, Journal of Drug Delivery and Therapeutics, 2017; 7(7):44-45.

13. Khan MA, Enhancement of solubility of poorly water soluble drugs diclofenac sodium by mixed solvency approach, Research Journal of Pharmaceutical Dosage Forms and Technology, 2013; 5(1):39-41.

14. Kendre PN, Pande VV, Chavan KM, Novel formulation strategy to enhance solubility of quercetin, Pharmacopoeiae, 2014; 5(3):358-370.

15. Kumar CJ, Kumar MD, Solubility enhancement of theophylline drug using mixed solvency approach, International Journal of Chemical Separation Technology, 2015; 12(1):1-4.

16. Gadade D, Lohade, TS, Lahoti SR, Rawat SS, Maheshwari RK, Solubility enhancement of oxolinic by mixed solvency approach, Indian Drugs, 2015; 55(6):34-40.

17. Jain S, Khan A, Jain SD, Maheshwari RK, Solubility enhancement of paracetamol by mixed solvency method, Research & Reviews: Journal of Computational Biology, 2019; 8(2):19-22.

18. Kushwaha A, Gupta MK, Gesswani A, Formulation and evaluation of optimized batch in situ gel of ondansetron hydrochloride, Pharmacia: An International Journal of Pharmaceutical Sciences, 2016; 3(1):11-16.

19. Kumar D, Domperidone nasal gel using fenugreek seed as mucoadhesive agent: water solubility problem sort-out, Trends in Pharmaceutics and Nanotechnology, 2019; 2(1):1-11.

20. Agrawal A, Maheshwari RK, Formulation development and evaluation of in situ nasal gel of poorly water soluble drug using mixed solvency concept, Asian Journal of Pharmaceutics (AJP), 2014; 5(3):131-140.

21. Maheshwari RK, Rajagopalan R, Formulation and evaluation of paracetamol syrup made by mixed-solvency concept, Der Pharmacia Lettre, 2012; 4(1):170-174.

22. Maheshwari RK, Rajagopalan R, Formulation and evaluation of tinidazole syrup made by mixed solvency concept technique, Der Pharmacia Lettre, 2011; 3(6):266-271.

23. Soni LK, Solanki SS, Maheshwari RK, Evaluation of analgesic, anti-inflammatory and ulcerogenic liability of oral solution (syrup) formulation developed by novel mixed solvency concept, Advances in Pharmacology & Toxicology, 2015; 16(2):21-30.

24. Gahlot N, Maheshwari RK, Formulation and development of vaginal films of poorly water soluble drug, metronidazole, using mixed solvency concept and their evaluations, Journal Of Drug Delivery And Therapeutics, 2018; 8(6):41-48. https://doi.org/10.22270/jddt.v8i6.20895

25. Carpenter G, Maheshwari RK, Formulation and development of fast dissolving oral film of a poorly soluble drug, frusemide with improved drug loading using mixed solvency concept and its evaluation, Journal of Drug Delivery and Therapeutics, 2018; 8(6):132-141. https://doi.org/10.22270/jddt.v8i6.2034

26. Mulani P, Maheshwari RK, Formulation development of aqueous topical solutions and gels of poorly water soluble drug nimesulide, using novel application of mixed solvency concept and their evaluations, International Journal of Science and Research (IJSR), 2018; 8(12):1521-1529.

27. Singh S, Maheshwari RK, Gahlot N, Formulation development of topical solutions of poorly water-soluble drug indomethacin employing novel application of mixed solvency concept and their evaluation, International Journal of Green Pharmacy (IGP), 2018; 12(2):73-79.

28. Maheshwari RK, Chaklan N, Singh S, Novel pharmaceutical application of mixed solvency concept for development of solid dispersions of piroxicam, European Journal of Biomedical and Pharmaceutical Sciences, 2015; (13):578-591.

29. Mansuk AG, Deshmukh D, Maheshwari RK, Pachpute T, Formulation optimization and characterization of solid dispersion of piroxicam prepared by novel application of mixed solvency concept, Pharmaceutical Resonance, 2020; 2(2):41-46.

30. Bagel J, Maheshwari RK, Novel application of mixed solvency concept in the development of fast dissolving solid dispersion of poorly water-soluble drug, torsemide and its evaluations, World Journal of Pharmaceutical Research, 2020; 9(1):1820-1839

31. Chouhan M, Gupta D, Chauke R, Maheshwari RK, Formulation and evaluation fast dissolving tablets oflovastatin using solid dispersion method, Journal of Drug Delivery & Therapeutics, 2019; 9(2-A):29-31.

32. Agrawal R, Maheshwari RK, Novel application of mixed solvency concept in the development of oral liquid solid system of a poorly soluble drug, cefixime and its evaluations, Journal of Drug Delivery and Therapeutics, 2018; 8(6-s):5-8. https://doi.org/10.22270/jddt.v8i6.s12167

33. Barua D, Indurkhya A, Maheshwari RK, Kumar P, Formulation of rifabutin liquid solid system using mixed solvency concept and their evaluation, International Journal of Pharmacy and Pharmaceutical Sciences, 2019; 4(2):2455-698.

34. Jain S, Maheshwari RK, Formulation development of oral liquid solid system of poorly water soluble drug, piroxicam, using mixed solvency concept and their evaluation, International Journal of Science and Research (IJSR), 2018; 8(12):1703-1711.

35. Rathod M, Agrawal S, Development and evaluation of furomeside microparticles made by mixed solvency concept, International Journal of Pharmaceutical Erudition, 2013; 2(4):J2-31.

36. Maheshwari RK, Chandna C, Mixed solvency concept in reducing surfactant concentration of self-emulsifying drug delivery systems of candesartan cilexetil using D-optimal mixture design, Asian Journal of Pharmaceutics, 2013; 7(2):83-91.

37. Maheshwari RK, Jain S, Padria A, Mukar C, Baghel BS, Maheshwari N, Eco-friendly extraction using solids - A novel application of mixed solvency concept, Journal of Drug Delivery & Therapeutics, 2019; 9(2):244-249 https://doi.org/10.22270/jddt.v9i2.2409

38. Padiyar A, Maheshwari RK, Jain S, Formulation and development of high concentration diclofenac sodium injection using mixed solvency concept and its evaluation, International Journal of Advanced Pharmaceutics, 2016; 6:78-84.

39. Jit P, Maheshwari RK, Formulation development of dry powder injection for reconstitution of poorly water-soluble drug, indomethacin, using mixed solvency concept and their evaluations, International Journal Of Pharmaceutical Research And Applications, 2021; 6 (2):314-326.

40. Jain A, Maheshwari RK, Novel application of mixed solvency concept in formulation and development of fast dissolving oral films of poorly water soluble drug, amldipine besylate and their evaluations, International Journal Of Pharmaceutical Research And Applications 2021; 6 (2):35-55.

41. Padria A, Maheshwari RK, Thakur Y, Ludhiani S, Formulation and development of model dry powder injection for reconstitution of poorly water soluble drug dizapam by using mixed solvency concept and their evaluations, International Journal Of Pharmaceutical Research And Applications, 2021; 6 (1):1286-1286.